| Meaghan Dayton, DPT | |
|
201 W Van Asche Loop, Fayetteville, AR 72703-4996 | |
| (479) 966-4491 | |
| (479) 966-3411 |
| Full Name | Meaghan Dayton |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 10 Years |
| Location | 201 W Van Asche Loop, Fayetteville, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578952834 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1255191 (Texas) | Secondary |
| 225100000X | Physical Therapist | PT4602 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Arkansas | 4082528955 | 1121 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.
Amid the coronavirus pandemic, scientists race to develop a vaccine that can help contain the spread of the virus. The coronavirus disease (COVID-19) has so far infected more than 3.18 million people across the globe. Now, early tests of a potential coronavirus vaccine have shown promise in pre-clinical trials.
An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer.
› Verified 6 days ago
| Provider Name | University Of Arkansas For Medical Sciences |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588654016 PECOS PAC ID: 4082528955 Enrollment ID: O20031219000706 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.
Amid the coronavirus pandemic, scientists race to develop a vaccine that can help contain the spread of the virus. The coronavirus disease (COVID-19) has so far infected more than 3.18 million people across the globe. Now, early tests of a potential coronavirus vaccine have shown promise in pre-clinical trials.
An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer.
› Verified 6 days ago
| Provider Name | University Of Arkansas For Medical Sciences |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1427461045 PECOS PAC ID: 4082528955 Enrollment ID: O20141117000407 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.
Amid the coronavirus pandemic, scientists race to develop a vaccine that can help contain the spread of the virus. The coronavirus disease (COVID-19) has so far infected more than 3.18 million people across the globe. Now, early tests of a potential coronavirus vaccine have shown promise in pre-clinical trials.
An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meaghan Dayton, DPT Po Box 251420, Little Rock, AR 72225-1420 Ph: (501) 686-8000 | Meaghan Dayton, DPT 201 W Van Asche Loop, Fayetteville, AR 72703-4996 Ph: (479) 966-4491 |
News Archive
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.
Amid the coronavirus pandemic, scientists race to develop a vaccine that can help contain the spread of the virus. The coronavirus disease (COVID-19) has so far infected more than 3.18 million people across the globe. Now, early tests of a potential coronavirus vaccine have shown promise in pre-clinical trials.
An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer.
› Verified 6 days ago
Karen Hairston, RPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2474 E Joyce Blvd, Suite 2, Fayetteville, AR 72703 Phone: 479-521-8326 Fax: 479-521-5439 | |
Fernando Castillo, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3383 N Mana Ct Ste 201, Fayetteville, AR 72703 Phone: 479-571-6780 | |
Kymbrly Hannah, RPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2474 E Joyce Blvd, Suite 2, Fayetteville, AR 72703 Phone: 479-521-8326 Fax: 479-521-5439 | |
Ms. Heather Kristine Vaughn, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1125 N College Ave, Fayetteville, AR 72703 Phone: 479-713-8630 Fax: 479-713-8639 | |
Megan Landry Wilson, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1923 E Joyce Blvd, Fayetteville, AR 72703 Phone: 479-442-7220 | |
Travis Alexander, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 3399 Black Forest Dr Ste 3, Fayetteville, AR 72704 Phone: 479-435-6712 Fax: 844-317-0394 | |
Winston Tyler Futrell, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2668 E Citizens Dr Ste 5, Fayetteville, AR 72703 Phone: 479-595-0711 |